{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:31:06Z","timestamp":1794047466965,"version":"4.8.0"},"reference-count":15,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"9","license":[{"start":{"date-parts":[[2024,3,28]],"date-time":"2024-03-28T00:00:00Z","timestamp":1711584000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"DOI":"10.3324\/haematol.2023.284917","type":"journal-article","created":{"date-parts":[[2024,3,28]],"date-time":"2024-03-28T05:35:36Z","timestamp":1711604136000},"page":"3071-3077","source":"Crossref","is-referenced-by-count":2,"title":["BCMA x CD3 T-cell engager in a patient with pentarefractory multiple myeloma and HIV: a clinical and immunological report"],"prefix":"10.3324","volume":"109","author":[{"given":"Leon","family":"Cords","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Schaefers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulaziz","family":"Kamili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"Cichutek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friedrich","family":"Haag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Polywka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Bokemeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Leypoldt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winfried","family":"Alsdorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian Schulze zur","family":"Wiesch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja C.","family":"Weisel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2024,3,28]]},"reference":[{"key":"66336","unstructured":"Moreau P, Kumar SK, San Miguel J. Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. Lancet Oncol. 2021; 22(3):e105-e118."},{"key":"66337","doi-asserted-by":"crossref","unstructured":"Moreau P, Garfall AL, van de Donk NWCJ. Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med. 2022; 387(6):495-505.","DOI":"10.1056\/NEJMoa2203478"},{"key":"66338","doi-asserted-by":"crossref","unstructured":"Moreau P, van de Donk NWCJ, Delforge M. Comparative efficacy of teclistamab versus current treatments in real-world clinical practice in the Prospective LocoMMotion Study in patients with triple-class-exposed relapsed and\/or refractory multiple myeloma. Adv Ther. 2023; 40(5):2412-2425.","DOI":"10.1007\/s12325-023-02480-7"},{"key":"66339","doi-asserted-by":"crossref","unstructured":"Hattenhauer ST, Mispelbaum R, Hentrich M, Boesecke C, Monin MB. Enabling CAR T-cell therapies for HIV-positive lymphoma patients - A call for action. HIV Med. 2023; 24(9):957-964.","DOI":"10.1111\/hiv.13514"},{"key":"66340","doi-asserted-by":"crossref","unstructured":"Uldrick TS, Ison G, Rudek MA. Modernizing clinical trial eligibility criteria: recommendations of the American Society of Clinical Oncology-Friends of Cancer Research HIV Working Group. J Clin Oncol. 2017; 35(33):3774-3780.","DOI":"10.1200\/JCO.2017.73.7338"},{"key":"66341","doi-asserted-by":"crossref","unstructured":"Tanko RF, Soares AP, Masson L. Residual T cell activation and skewed CD8+ T cell memory differentiation despite antiretroviral therapy-induced HIV suppression. Clin Immunol. 2018; 195:127-138.","DOI":"10.1016\/j.clim.2018.06.001"},{"key":"66342","doi-asserted-by":"crossref","unstructured":"Weinhold N, Salwender HJ, Cairns DA. Chromosome 1q21 abnormalities refine outcome prediction in patients with multiple myeloma - a meta-analysis of 2,596 trial patients. Haematologica. 2021; 106(10):2754-2758.","DOI":"10.3324\/haematol.2021.278888"},{"key":"66343","unstructured":"Kumar S, Paiva B, Anderson KC. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016; 17(8):e328-e346."},{"key":"66344","doi-asserted-by":"crossref","unstructured":"Eberhard JM, Angin M, Passaes C. Vulnerability to reservoir reseeding due to high immune activation after allogeneic hematopoietic stem cell transplantation in individuals with HIV-1. Sci Transl Med. 2020; 12(542):eaay9355.","DOI":"10.1126\/scitranslmed.aay9355"},{"key":"66345","doi-asserted-by":"crossref","unstructured":"Firestone RS, McAvoy D, Shekarkhand T. CD8 effector T cells enhance response in BCMA-exposed and -na\u00efve multiple myeloma. Blood Adv. 2024; 8(7):1600-1611.","DOI":"10.1182\/bloodadvances.2023011225"},{"key":"66346","doi-asserted-by":"crossref","unstructured":"Schulze zur Wiesch J, Thomssen A, Hartjen P. Comprehensive analysis of frequency and phenotype of T regulatory cells in HIV infection: CD39 expression of FoxP3+ T regulatory cells correlates with progressive disease. J Virol. 2011; 85(3):1287-1297.","DOI":"10.1128\/JVI.01758-10"},{"key":"66347","doi-asserted-by":"crossref","unstructured":"Sims GP, Ettinger R, Shirota Y, Yarboro CH, Illei GG, Lipsky PE. Identification and characterization of circulating human transitional B cells. Blood. 2005; 105(11):4390-4398.","DOI":"10.1182\/blood-2004-11-4284"},{"key":"66348","doi-asserted-by":"crossref","unstructured":"Sim BZ, Longhitano A, Er J, Harrison SJ, Slavin MA, Teh BW. Infectious complications of bispecific antibody therapy in patients with multiple myeloma. Blood Cancer J. 2023; 13(1):34.","DOI":"10.1038\/s41408-023-00808-8"},{"key":"66349","doi-asserted-by":"crossref","unstructured":"Mazahreh F, Mazahreh L, Schinke C. Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis. Blood Adv. 2023; 7(13):3069-3074.","DOI":"10.1182\/bloodadvances.2022009435"},{"key":"66350","doi-asserted-by":"crossref","unstructured":"Stevenson M, Stanwick TL, Dempsey MP, Lamonica CA. HIV-1 replication is controlled at the level of T cell activation and proviral integration. EMBO J. 1990; 9(5):1551-1560.","DOI":"10.1002\/j.1460-2075.1990.tb08274.x"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.284917\/76837","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.284917\/77453","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11524\/76837","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:06:04Z","timestamp":1794045964000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2023.284917"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,28]]},"references-count":15,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,9,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2023.284917","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3,28]]}}}